Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer

A breast medical oncologist reviews oral SERDs currently in development for the treatment of patients with ER+/HER2 metastatic breast cancer, highlighting camizestrant, imlunestrant, and giredestrant.

EP: 1.Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer

EP: 2.Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer

EP: 3.Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

EP: 4.ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

EP: 5.Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

EP: 6.Elacestrant: Treatment Considerations, Including Dosing and Compliance

EP: 7.Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

EP: 8.Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer

EP: 9.Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer

EP: 10.Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer

EP: 11.The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer

Now Viewing

EP: 12.Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer

EP: 13.Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer

Related Videos

Related Content

Advertisement

July 3rd 2025

Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control

Jared Kaltwasser

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 2nd 2025

Approved Hidradenitis Suppurativa Treatments and Pipeline Show Similar Efficacy, Safety Without Head-to-Head Trials

Cameron Santoro

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable efficacy and safety, offering hope for patients often dissatisfied with current treatment options.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 1st 2025

Sun Exposure Risks Brought to Light During UV Safety Awareness Month

Brooke McCormick

July is UV Safety Awareness Month, highlighting the growing risks of UV radiation and encouraging the use of protective measures to reduce sun-related health threats.

July 1st 2025

Challenges and Opportunities for AI in Melanoma Detection

AJMC Contributor

While artificial intelligence (AI) holds promise to improve the diagnosis of melanoma, researchers of a new review outlined challenges with these novel approaches.

Related Content

Advertisement

July 3rd 2025

Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control

Jared Kaltwasser

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 2nd 2025

Approved Hidradenitis Suppurativa Treatments and Pipeline Show Similar Efficacy, Safety Without Head-to-Head Trials

Cameron Santoro

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable efficacy and safety, offering hope for patients often dissatisfied with current treatment options.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 1st 2025

Sun Exposure Risks Brought to Light During UV Safety Awareness Month

Brooke McCormick

July is UV Safety Awareness Month, highlighting the growing risks of UV radiation and encouraging the use of protective measures to reduce sun-related health threats.

July 1st 2025

Challenges and Opportunities for AI in Melanoma Detection

AJMC Contributor

While artificial intelligence (AI) holds promise to improve the diagnosis of melanoma, researchers of a new review outlined challenges with these novel approaches.